Investment Analysts’ Weekly Ratings Updates for QuidelOrtho (QDEL)

Several analysts have recently updated their ratings and price targets for QuidelOrtho (NASDAQ: QDEL):

• 7/8/2026 – QuidelOrtho had its price target raised by Citigroup Inc. from $13.00 to $18.00. They now have a “neutral” rating on the stock.
• 7/1/2026 – QuidelOrtho had its price target raised by JPMorgan Chase & Co. from $11.00 to $12.00. They now have an “underweight” rating on the stock.
• 6/29/2026 – QuidelOrtho had its “hold” rating reaffirmed by Jefferies Financial Group Inc..
• 6/28/2026 – QuidelOrtho was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/20/2026 – QuidelOrtho was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/15/2026 – QuidelOrtho was upgraded by Zacks Research from “strong sell” to “hold”.

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.